Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: Review of current information on efficacy and safety

Clinical Infectious Diseases

Volumn 23, Issue SUPPL. 1, 1996, Pages

  Goldstein, Ellie J C ^a,b  

^a Santa Monica UCLA Medical Center   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; CLINAFLOXACIN; CLINDAMYCIN; GENTAMICIN; GREPAFLOXACIN; LEVOFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SITAFLOXACIN; SPARFLOXACIN; TROVAFLOXACIN;

ANAEROBIC BACTERIUM; ANAEROBIC INFECTION; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BACTEROIDES; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FUSOBACTERIUM; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PHOTOSENSITIZATION; PORPHYROMONAS; PREVOTELLA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VASCULITIS;

EID: 0029849937     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/23.supplement_1.s25     Document Type: Article

References (15)

1. Turner P, Edwards R, Western V, Gazis A, Ispahani P, Greenwood D. Simultaneous resistance to metronidazole, co-amoxiclav, and imipenem in clinical isolate of Bacteroides fragilis. Lancet 1995;345:1275-7.
2. Goldstein EJC. Patterns of susceptibility of fluoroquinolones among anaerobic bacterial isolates in the United States. Clin Infect Dis 1993; 16(suppl 4):S377-81.
3. Campoli-Richards DM, Monk JP, Price A, Benfield P, Todd PA, Ward A. Ciprofloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1988;35:373-447.
4. Neu HC. New oral and parenteral quinolones: a summary. Am J Med 1989;87(suppl 5A):283S-7S.
5. Fass RJ. Treatment of skin and soft tissue infections with oral ciprofloxacin. J Antimicrob Chemother 1986;18(suppl D):153-7.
6. Wood MJ, Logan MN. Ciprofloxacin for soft tissue infections. J Antimicrob Chemother 1986;18(suppl D):159-64.
7. Crombleholme WR, Schachter J, Ohm-Smith M, Luft J, Whidden R, Sweet RL. Efficacy of single-agent therapy for the treatment of acute pelvic inflammatory disease with Ciprofloxacin. Am J Med 1989; 87(suppl 5A): 142S-7S.
8. Ball P. Ciprofloxacin: an overview of adverse experiences. J Antimicrob Chemother 1986; 18(suppl D): 187-93.
9. Monk JP, Campoli-Richards DM. Ofloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1987; 33:346-91.
10. Graninger W, Presterl E, Walzl B, Lackner R, Haslinger B, Hackl W. Intravenous ofloxacin in severe infections. J Antimicrob Chemother 1990;26(suppl D):123-35.
11. Gentry LO, Rodriguez-Gomez G, Zeluff BJ, Khoshdel A, Price M. A comparative evaluation of oral ofloxacin versus intravenous cefotaxime therapy for serious skin and skin structure infections. Am J Med 1989; 87(suppl 6C):57S-60S.
12. Goldstein EJC, Citron DM. Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria. Antimicrob Agents Chemother 1992;36:1158-62.
13. Goldstein EJC, Citron DM. Susceptibility of anaerobic bacteria isolated from intra-abdominal infections to ofloxacin and interaction of ofloxacin with metronidazole. Antimicrob Agents Chemother 1991;35:2447-9.
14. Tack KJ, Smith JA. The safety profile of ofloxacin. Am J Med 1989; 87(suppl 6C):78S-81S.
15. Appelbaum PC. Quinolone activity against anaerobes: microbiological aspects. Drugs 1995;49(suppl 2):76-80.